for PROVENGE(R) (sipuleucel-T).
-- Completed the target enrollment of 500 patients in the IMPACT study of
PROVENGE for advanced prostate cancer
-- Promoted Dr. Mark Frohlich to senior vice president of clinical
affairs and chief medical officer
-- Cancer Immunology, Immunotherapy publication on CD54 as surrogate
marker of antigen presenting cell activation
-- Data correlating the cumulative potency of PROVENGE to overall
survival presented at American Society of Clinical Oncology's
-- Received European patent covering PROVENGE and Active Cellular
Immunotherapy (ACI) platform technology
"The most significant event in 2007 was the FDA advisory panel that voted in support of the substantial evidence of efficacy of PROVENGE for men with advanced prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We have begun 2008 by accelerating the final data analysis of the pivotal IMPACT study by approximately one year and we look forward to completing the interim analysis of this study in the second half of this year. We are committed to bringing what could be this first of its kind therapy to prostate cancer patients as soon as possible, as well as advancing other product candidates in our pipeline."
Conference Call Information
Dendreon will host a conference call today at 8:00 a.m. PT, 11:00 a.m.
ET. To access the live call, dial 1-877-548-7901 (domestic) or
+1-719-325-4844 (international). The call will also be audio webcast and
will be available from the Company's website at http://www.dendreon.com
under the "Investor/Webcasts and Presentations" section. A recorded
rebroadcast will be available for interested parties unable to participate
in the live conference call by dialing 1-888-203-1112 or +1-719-457-
|SOURCE Dendreon Corporation|
Copyright©2008 PR Newswire.
All rights reserved